A contraceptive patch developed by Agile Therapeutics was awarded FDA approval late Friday, clearing the way for a new birth control option to reach the market.
The Agile (NASDAQ: AGRX) product, called Twirla, deliver delivers a combination of hormones via a proprietary skin patch applied once a week. It’s the first FDA approved product for the Princeton, NJ-based company.
For Agile, the regulatory approval has been a long time coming. The company submitted applications for FDA review twice before, receiving rejections in 2013 and 2017. The 2017 rejection cited deficiencies in the manufacturing process and questions about the patch’s adhesion… Read more »
UNDERWRITERS AND PARTNERS
